# Roivant Sciences Ltd.: insider transactions

ROIV · Nasdaq · CIK 1635088 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/roiv.md) · [Financials](/companies/roiv/financials.md) · [Filings](/companies/roiv/filings.md) · [Insiders](/companies/roiv/insiders.md)

## All transactions: 4

Non-derivative transactions reported on Forms 4, newest first. Codes P (purchase) and S (sale) are open-market trades. Reported price is as stated on the form, not a market price. Filter with ?type= `open-market`, `purchase`, `sale`.

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2026-10-23 | [Momtazee James C](/insiders/1209181.md) | Director | Tax withholding (F) | 77 | $36.49 | $2.8k | [Form 4](/filings/0001209181-26-000009.md) |
| 2026-10-23 | [Momtazee James C](/insiders/1209181.md) | Director | Grant or award (A) | 383 | $0.00 | $0 | [Form 4](/filings/0001209181-26-000009.md) |
| 2026-10-20 | [Venker Eric](/insiders/1801917.md) | President & Immunovant CEO, Officer | Sale (S) | 14,144 | $35.42 | $501.0k | [Form 4](/filings/0001635088-26-000116.md) |
| 2026-10-20 | [Venker Eric](/insiders/1801917.md) | President & Immunovant CEO, Officer | Sale (S) | 185,856 | $35.09 | $6.5m | [Form 4](/filings/0001635088-26-000116.md) |

Source: SEC EDGAR, Forms 4. Last ingested by Listed: Nov 3, 2026, 20:10 ET. No prices; not investment advice.